XERS News and Press, Xeris Pharmaceuticals Inc. From 08/10/21

Six multi-billion dollar deals announced last week. VICI Properties acquires MGM Growth Properties for $17.2 billion. Veoneer receives a superior bid from Qualcomm. For further details see: Merger Arbitrage Mondays - Veoneer Receives A Superior Bid From Qualcomm

Gainers: Profound Medical (NASDAQ:PROF) +28%, STAAR Surgical (NASDAQ:STAA) +19%, AdaptHealth (NASDAQ:AHCO) +17%, Flora Growth (NASDAQ:FLGC) +16%, Invacare (NYSE:IVC) +15%. Losers: Inogen (NASDAQ:INGN) -32%, Karyopharm Therapeutics (NASDAQ:KPTI) ...

Fastly FSLY -23% on Q2 earnings release  Karyopharm Therapeutics KPTI -18% on Q2 earnings release  Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...

Xeris Pharmaceuticals (NASDAQ:XERS): Q2 GAAP EPS of -$0.41 misses by $0.14. Revenue of $8.84M (+346.5% Y/Y) misses by $4.95M. Press Release For further details see: Xeris Pharmaceuticals EPS misses by $0.14, misses on revenue

Gvoke® prescription volume up 32% versus prior quarter Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter Strong cash position of $116 million ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) ( Xeris ) today announced in accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the Irish Takeover Rules ) that, as of the close of business on July 28, 2021, Xeris' issued share capital, excluding tre...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial re...

Barry Deutsch is stepping down as CFO; remains key employee through the anticipated closing of previously announced transaction Steve Pieper, VP of Finance, assumes the role of CFO Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leverag...

Xeris Pharmaceuticals (XERS) has signed an exclusive agreement with Tetris Pharma for the commercialization of Ogluo in a deal worth as much as $71M.The agreement, in the European Economic Area, United Kingdom, and Switzerland, allows for the treatment of severe hypoglycae...

Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UK Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulati...